|Over a quarter ago|
Tocagen to host conference call » 05:2402/2002/20/20
Conference call to…
Conference call to discuss agreement to merge with Forte Biosciences, Inc. will be held on February 20 at 8:30 am. Webcast Link
Tocagen, Forte Biosciences to merge » 20:1402/1902/19/20
Tocagen and Forte…
Tocagen and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction. The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. Upon stockholder approval, the combined company is expected to operate under the name Forte Biosciences and trade on the Nasdaq Capital Market under the ticker symbol FBRX. Forte's lead asset, FB-401, is a potentially first-in-class, live biotherapeutic being developed as a topical therapy for the treatment of inflammatory skin diseases, including atopic dermatitis. In a Phase 1/2a trial in adults and pediatrics, FB-401 demonstrated significant efficacy and a favorable safety and tolerability profile. The full trial results will be submitted for publication in a peer-reviewed journal in the first half of 2020. A randomized Phase 2 trial is planned to commence in mid-2020 in adults and pediatrics with atopic dermatitis, providing an expected data readout in mid-2021.
Tocagen says Phase 3 trial did not meet primary, secondary endpoints » 16:0811/2211/22/19
Tocagen announced presentation of the full results from the Toca 5 Phase 3 trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma at the Society for Neuro-Oncology Annual Meeting. The data were presented on behalf of the Toca 5 clinical investigators by Timothy Cloughesy, M.D., professor of neurology and director of the neuro-oncology program at the University of California, Los Angeles and principal investigator for the Toca 5 trial. The trial did not meet the primary or secondary endpoints. The safety, tolerability and adverse event profile of Toca 511 & Toca FC was as expected for this patient population. "The positive outcome for patients at second recurrence in the Toca 5 trial are compelling, despite the disappointment of the overall trial results," said Dr. Cloughesy. "Combined with an acceptable safety profile, these data support a potential opportunity to address the high unmet needs of this well-defined patient population and should inform any future development of the Toca 511 & Toca FC regimen."
Tocagen reports Q3 EPS (78c), consensus (70c) » 16:3311/1211/12/19
License revenue was less…
License revenue was less than $0.1M for the quarter ended September 30, compared to $18M for the quarter ended September 30, 2018. The 2018 revenue was related to upfront payments and milestones earned under our license agreement with Apollobio. Q3 revenue consensus $500,000.
Tocagen announces restructuring, to reduce workforce by about 65% » 08:0110/0310/03/19
Tocagen announced a…
Tocagen announced a restructuring to focus its resources on the clinical development of Toca 511 and Toca FC. Tocagen will reduce its workforce by approximately 65%, resulting in an estimated 30 remaining full-time employees by the end of the year. The company plans to provide financial guidance in the fourth quarter.
Tocagen downgraded to Neutral from Buy at Citi » 05:1009/1309/13/19
Citi analyst Mohit Bansal…
Citi analyst Mohit Bansal downgraded Mohit Bansal to Neutral from Buy and cut his price target for the shares to $1 from $20. The failure of TOCA 5 could make investors question Tocagen's platform and future given that most of its pipeline relies on the same technology, Bansal tells investors in a research note. With management conducting a business review to chart out the future direction for the company, the analyst moves to the sidelines pending more clarity on a future direction.
Tocagen downgraded to Neutral from Buy at Chardan » 05:0809/1309/13/19
Chardan analyst Geulah…
Chardan analyst Geulah Livshits downgraded Tocagen to Neutral from Buy with a price target of $1, down from $10, after the company announced its pivotal Phase III trial in recurrent high grade glioma missed primary and secondary endpoints. The analyst sees limited pipeline visibility for Tocagen.
Fly Intel: Wall Street's top stories for Thursday » 16:2409/1209/12/19
ORCL, T, GOOG, GOOGL, ENPH, SEDG, MRNA, LKQ, TOCA, GRPN, YELP
Stocks climbed during…
Tocagen downgraded to Neutral from Buy at B. Riley FBR » 13:2309/1209/12/19
B. Riley FBR analyst…
B. Riley FBR analyst George Zavoico downgraded Tocagen to Neutral from Buy with a $1 price target after the company said the Phase 3 pivotal Toca 5 study for the treatment of recurrent high-grade gliomas missed the primary endpoint of overall survival.
Tocagen downgraded to Neutral from Buy at Ladenburg » 12:4509/1209/12/19
Ladenburg analyst Wangzhi…
Ladenburg analyst Wangzhi Li downgraded Tocagen to Neutral from Buy after the company said the Phase 3 pivotal Toca 5 study for the treatment of recurrent high-grade gliomas missed the primary endpoint of overall survival.